Malignant hyperthermia can be triggered by which of the following anesthetic agents?

Malignant hyperthermia can be triggered by which of the following anesthetic agents?

• A. Sevoflurane
• B. Halothane
• C. Desflurane
• D. Both Halothane and Desflurane

Answer: (D)

Malignant hyperthermia is a rare but potentially life-threatening reaction to certain anesthetic agents, characterized by a rapid increase in body temperature and severe muscle contractions. It is primarily associated with the use of volatile anesthetics and succinylcholine, a neuromuscular blocker. Halothane is a well-known trigger for malignant hyperthermia, as it has been documented in multiple studies and case reports as a direct cause of this severe reaction. The mechanism involves a hypermetabolic state initiated by the release of calcium from the sarcoplasmic reticulum of muscle cells. Desflurane, while less commonly associated with malignant hyperthermia than halothane, can still trigger episodes in susceptible individuals. Though it has a faster onset and recovery profile, the potential for inducing malignant hyperthermia exists due to its volatile nature. Combining these two agents in the context of the question demonstrates an understanding that both have the capacity to elicit a malignant hyperthermic reaction in individuals with a predisposition to the condition. This highlights the importance of pre-anesthetic assessment in identifying patients at risk and opting for safer alternatives in their anesthetic management.

Malignant hyperthermia is a rare but potentially life-threatening reaction to certain anesthetic agents, characterized by a rapid increase in body temperature and severe muscle contractions. It is primarily associated with the use of volatile anesthetics and succinylcholine, a neuromuscular blocker.

Halothane is a well-known trigger for malignant hyperthermia, as it has been documented in multiple studies and case reports as a direct cause of this severe reaction. The mechanism involves a hypermetabolic state initiated by the release of calcium from the sarcoplasmic reticulum of muscle cells.

Desflurane, while less commonly associated with malignant hyperthermia than halothane, can still trigger episodes in susceptible individuals. Though it has a faster onset and recovery profile, the potential for inducing malignant hyperthermia exists due to its volatile nature.

Combining these two agents in the context of the question demonstrates an understanding that both have the capacity to elicit a malignant hyperthermic reaction in individuals with a predisposition to the condition. This highlights the importance of pre-anesthetic assessment in identifying patients at risk and opting for safer alternatives in their anesthetic management.